iTeos Therapeutics to Present Phase 2 GALAXIES Lung-201 Interim Data at ESMO 2024

On August 20, 2024, iTeos Therapeutics, Inc. (Nasdaq: ITOS) announced that interim data from their Phase 2 study, GALAXIES Lung-201, will be presented at the European Society for Medical Oncology (ESMO) Congress 2024, scheduled to take place from September 13-17, 2024, in Barcelona, Spain. This study is sponsored by iTeos' development partner, GSK, and evaluates the combination of belrestotug and dostarlimab in patients with previously untreated, unresectable, locally advanced, or metastatic PD-L1 high non-small cell lung cancer (NSCLC). The data will be featured in a late-breaking oral presentation.

The presentation titled "Interim Analysis of GALAXIES Lung-201: Phase 2, Randomized, Open-label Platform Study of Belrestotug Plus Dostarlimab in Patients with Previously Untreated Locally Advanced/Metastatic PD-L1 High Non-Small Cell Lung Cancer (NSCLC)" will be presented on September 14, 2024, at 8:30 am CEST. The study holds the abstract number LBA52 and will be part of the Proffered Paper Session on metastatic NSCLC.

iTeos Therapeutics is at the forefront of developing next-generation immuno-oncology therapeutics aimed at treating cancer patients. Utilizing in-depth knowledge of tumor immunology, iTeos designs novel therapeutic candidates that potentially restore the immune system's ability to fight cancer. The company's innovative pipeline includes three programs in clinical stages, focusing on new immunosuppressive pathways. These pathways, including the TIGIT/CD226 axis and the adenosine pathway, are targeted through products that have optimized pharmacologic properties to enhance clinical outcomes. iTeos is based in Watertown, Massachusetts, with a research center in Gosselies, Belgium.

Belrestotug is a monoclonal antibody (mAb) belonging to the human immunoglobulin G1 (IgG1) class. This antibody targets TIGIT (T cell immunoglobulin and ITIM domain), a critical inhibitory receptor involved in dampening both innate and adaptive immune responses against cancer. As a high-affinity, potent anti-TIGIT mAb, belrestotug is engineered to boost antitumor responses through a multifaceted immunomodulatory mechanism. This mechanism involves engagement with both TIGIT and FcγR, a key immune response regulator that induces cytokine release and antibody-dependent cellular cytotoxicity (ADCC). This therapeutic candidate is undergoing clinical trials for multiple indications in collaboration with GSK.

The data from the GALAXIES Lung-201 study aims to provide insights into the efficacy and safety of the belrestotug and dostarlimab combination in treating patients with high PD-L1 expression NSCLC. High PD-L1 expression typically indicates a substantial presence of this protein, which helps tumors evade the immune system. By combining belrestotug and dostarlimab, the study seeks to determine whether this therapeutic duo can effectively counteract this immune evasion, offering a new treatment avenue for patients with advanced or metastatic NSCLC.

The announcement highlights the ongoing efforts of iTeos and their collaboration with GSK in exploring innovative cancer therapies. With the interim data set to be discussed at a major oncology congress, the presentation marks a significant milestone in the development of new treatment strategies for lung cancer. As the global medical community focuses on advancing cancer treatment, the findings from this study are eagerly anticipated.